Zhong Yong, Pei Ying-Hao, Wang Jun, Chen Jiao, Jiang Shi-Sen, Gong Jian-Bin
From Jinling Hospital, Department of Cardiology, Nanjing University, School of Medicine , Nanjing , P. R. China.
Scand J Clin Lab Invest. 2014 Oct;74(7):582-7. doi: 10.3109/00365513.2014.921324. Epub 2014 May 30.
Myocardial bridging (MB), a common benign coronary anomaly, may bring about some unwanted complications such as angina-like chest pain. The only way of MB detection is coronary arteriography or coronary computed tomographic angiography, which is costly and invasive. This study intended to profile a panel of circulating microRNAs (miRNAs) as potential biomarkers for the diagnosis of MB.
Using TaqMan Low-Density Array followed by quantitative reverse transcriptase PCR (qRT-PCR) validation, we analyzed the expression of miRNAs in serum samples from 90 MB patients and 50 non-MB controls.
The Low-Density Array data showed that 196 miRNAs were differentially expressed in MB patient sera in comparison with controls. After qRT-PCR validation and receiver operating characteristic (ROC) analysis, a list of five miRNAs (miR-29b, miR-151-3p, miR-126, miR-503-3p and miR-645) showed the ability to distinguish MB patients from controls. The area under curve (AUC) values range from 0.722-0.938.
We have demonstrated that this panel of five serum miRNAs is expected to become potential non-invasive biomarkers for detection of MB.
心肌桥（MB）是一种常见的良性冠状动脉异常，可能引发一些不良并发症，如心绞痛样胸痛。检测MB的唯一方法是冠状动脉造影或冠状动脉计算机断层血管造影，这些方法成本高且具有侵入性。本研究旨在剖析一组循环微小RNA（miRNA）作为诊断MB的潜在生物标志物。
我们使用TaqMan低密度阵列，随后进行定量逆转录聚合酶链反应（qRT-PCR）验证，分析了90例MB患者和50例非MB对照血清样本中miRNA的表达。
低密度阵列数据显示，与对照组相比，196种miRNA在MB患者血清中差异表达。经过qRT-PCR验证和受试者工作特征（ROC）分析，五种miRNA（miR-29b、miR-151-3p、miR-126、miR-503-3p和miR-645）能够区分MB患者和对照组。曲线下面积（AUC）值范围为0.722 - 0.938。
我们已经证明，这组五种血清miRNA有望成为检测MB的潜在非侵入性生物标志物。
